We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Aptamer Group Plc | LSE:APTA | London | Ordinary Share | GB00BNRRP542 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.02 | 5.48% | 0.385 | 27,001,302 | 11:23:45 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.37 | 0.40 | 0.385 | 0.365 | 0.365 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 860k | -2.96M | -0.0015 | -2.53 | 7.01M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:06:16 | O | 790,000 | 0.3822 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/12/2024 | 07:00 | UK RNS | Aptamer Group PLC Holding(s) in Company |
| 10/12/2024 | 12:54 | ALNC |  DIRECTOR DEALINGS: Helios Towers director buys GBP200,000 in shares |
| 09/12/2024 | 15:30 | UK RNS | Aptamer Group PLC Notification of dealings by a director/PDMR |
| 09/12/2024 | 13:47 | UK RNS | Aptamer Group PLC Notification of dealings by a director/PDMR |
| 09/12/2024 | 07:00 | UK RNS | Aptamer Group PLC Grant of Options and Director Fee Shares |
| 06/12/2024 | 07:00 | UK RNS | Aptamer Group PLC New Scientific Advisory Board Members |
| 05/12/2024 | 19:52 | ALNC | EARNINGS AND TRADING: Synectics deal wins; TruFin to beat expectations |
| 05/12/2024 | 07:00 | UK RNS | Aptamer Group PLC Technical Update |
| 04/12/2024 | 07:00 | UK RNS | Aptamer Group PLC Investor Webinar |
| 29/11/2024 | 11:05 | UK RNS | Aptamer Group PLC Results of 2024 Annual General Meeting |
Aptamer (APTA) Share Charts1 Year Aptamer Chart |
|
1 Month Aptamer Chart |
Intraday Aptamer Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 15/12/2024 | 10:46 | ☆☆ Aptamer Group - Novel Antibody Mimetics (Optimers) ☆☆ | 5,657 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 15/12/2024 08:20 by Aptamer Daily Update Aptamer Group Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker APTA. The last closing price for Aptamer was 0.37p.Aptamer currently has 1,920,000,000 shares in issue. The market capitalisation of Aptamer is £7,296,000. Aptamer has a price to earnings ratio (PE ratio) of -2.53. This morning APTA shares opened at 0.37p |
Posted at 13/12/2024 11:10 by someuwin free stock charts from uk.advfn.com...These are the targets they've set themselves two days ago to get their significant options payouts - one third at 1.4p, one third at 2.0p and final third at 2.5p. These are set multiples higher than the current share price but they clearly believe they will be achieved. Thus this is the time to be accumulating as much stock as you can at these artificially low levels imo... Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "This share option package forms part of our long-term incentive plan designed to reward staff and management for delivering significant value to the majority of our shareholders. The Group has set aggressive share price targets, which I am confident we can achieve given the calibre of customers we are dealing with and the progress we have made on a number of opportunities reported on recently, both commercially and scientifically. I am excited by the rapid progress the team are making; their focus and the quality of their work is paving the way for great things to come. Our platform technology is gaining increasing traction in the marketplace, and we are well positioned, with a skilful and knowledgeable team and our newly appointed Scientific Advisory board, to be able to take advantage of this." |
Posted at 13/12/2024 08:31 by someuwin Alzheimer's Test.Two revenue streams - at home lateral flow test strips. and Clinical device. APTA Aptamers have been validated - They work and will detect Alzheimer's twenty years before symptoms appear! FDA awarded ROCHE the first and only early detection test this year but this requires blood test. APTA are closer than anyone to produce a simple saliva based early detection test. Alzheimer's test market will grow to 7bn per year. APTA could be a major early mover in this market. And that's just one of APTA's multiple pipelines. |
Posted at 11/12/2024 11:54 by purchaseatthetop Let’s hope they are more relevant than the Oct 23 similar announcement“The new options will have an exercise price of 1p, which is equal to the price at which the Company's fundraise was completed in July/August of this year. The new options will be subject to stretching performance targets as follows: (i) 16 per cent, on announcement of FY24 audited results in line with expectations and the share price having remained at or above 4 times the issue price for at least 3 months; (ii) 24 per cent, on announcement of FY25 audited results in line with expectations and the share price having remained at or above 7 times the issue price for at least 3 months; (iii) 40 per cent, on announcement of FY26 audited results in line with expectations and the share price having remained at or above 10 times the issue price for at least 3 months; (iv) 10 per cent, on announcement of FY26 audited results in line with expectations and the share price having remained at or above 30 times the issue price for at least 3 months; and (v) 10 per cent, on announcement of FY26 audited results in line with expectations and the share price having remained at or above 50 times the issue price for at least 3 months.” Now cancelled. By the way, anybody found any RNS saying y.e 30/6/25 revenue will be higher than £1.2m? |
Posted at 11/12/2024 11:29 by someuwin free stock charts from uk.advfn.com...These are the targets they've set themseleves two days ago to get their significant options payouts - one third at 1.4p, one third at 2.0p and final third at 2.5p. These are set multiples higher than the current share price but they clearly believe they will be achieved. Thus this is the time to be accumulating as much stock as you can at these artificailly low levels imo... Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "This share option package forms part of our long-term incentive plan designed to reward staff and management for delivering significant value to the majority of our shareholders. The Group has set aggressive share price targets, which I am confident we can achieve given the calibre of customers we are dealing with and the progress we have made on a number of opportunities reported on recently, both commercially and scientifically. I am excited by the rapid progress the team are making; their focus and the quality of their work is paving the way for great things to come. Our platform technology is gaining increasing traction in the marketplace, and we are well positioned, with a skilful and knowledgeable team and our newly appointed Scientific Advisory board, to be able to take advantage of this." |
Posted at 09/12/2024 07:40 by purchaseatthetop 9/10/23 options RNS“The proposed options are designed to provide a material incentive to the Directors and other staff, but on stretching revenue and share price performance criteria as set out below, which include achieving returns of at least 4-times and up to 50-times the 1p option exercise price. 60% of the options only vest if the prevailing share price reaches 10-times the option exercise price.” And “Dr Arron Tolley has agreed to the cancellation of 700,000 existing options with an exercise price of 7.675p each and Dr David Bunka has agreed to the cancellation of 32,600 and 61,400 existing options with exercise prices of 15.54p and 7.675p each respectively.” I think they can copy and paste the paragraph sny number of times in the future. |
Posted at 06/12/2024 21:39 by purchaseatthetop To be fair, he was spot on!“bones698 - 23 Jul 2024 - 04:27:55 - 4866 of 5506 ☆☆ Aptamer Group - Novel Antibody Mimetics (Optimers) ☆☆ - APTA For the record, have you looked at my record for calling fund raises on companies and that have gone on to do them? Polx, Gdr, sce, Avacta, dest, vrs etc to name a few, it's the nature of small companies. Once they are funded to a point they achieve break even then it's different but until that point dillution will keep happening.The key is timing it right. As for todays question yes I fully believe they will have to raise funds here in the near future. Cash burn was due to run out next month before the recent deals, however that might extend it slightly longer depending on their forecast model v cash burn. Those deals will not be received in full upfront but spread out over the duration of the deal,common practice. Revenues aren't enough to break even so they have been burning cash personally I think they are very close to needing to raise money in the next few months. As I posted above the comments in the trading updates were mentioned in the first but not the second. As for the fund raise it's going to be quite painful with a mkt cap of 3m trying to raise say 2m is going to require a significant discount to the current share price There's also a chance they go private which would not be good news so I would wait to until funding is sorted if your looking to buy in here. There is a small chnace they could get funding another way but this is unlikely and why it usually ends up being a rights issue, shareholders tend to hope this is an option but in relaity it rarely is and ends up with a dillutive raise.” Next day……hug |
Posted at 06/11/2024 07:04 by affc21 Aptamer Group plc ("Aptamer", the "Company" or the "Group") Commercial Trading Update Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to provide an update on contracts signed since its financial year ended 30 June 2024. Aptamer has secured new contracts worth up to £471,000 continuing the positive commercial traction achieved during the last quarter of the previous financial year. These contracts include multiple agreements, including two from top 20 and one from a top 5 global pharmaceutical companies, totalling up to £340,000. These projects are aimed at developing Optimers as critical reagents to support active clinical development programmes and facilitate the analysis of novel therapeutics. A significant proportion of these deals involve repeat customers who are advancing Aptamer's binders within their internal pipelines, with some signalling intent for long-term licensing revenues. This ongoing traction highlights Aptamer's role in supporting key industry players and reinforces our position as a key player in the market.These new contracts illustrate Aptamer's increasing commercial traction and the Group's ability to secure repeat business from top pharmaceutical companies. Aptamer now has booked revenue contracts of up to c. £1.2m to recognise throughout FY25 (Jun 25 year-end) and an increased sales pipeline from £2.1m in July 2024 to £4.0m as of today.Dr Arron Tolley, Chief Executive Officer of Aptamer Group said: "Following the fundraise in August 2024, I am pleased to report that the sustained focus of our commercial team continues to bear fruit. We are advancing steadily towards our revenue and potential licensing goals for FY 25 with the best part of 7 months left in the financial year. Revenue generation and increased income from licensing form a pivotal component of the Group's strategy to deliver shareholder value and I look forward to updating you on future contracts and key project updates."? - Ends -? |
Posted at 17/10/2024 09:33 by someuwin 17 October 2024Aptamer Group plc ("Aptamer", the "Company" or the "Group") Notice of Results and Investor Presentation Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will announce its full year results for the year ended 30 June 2024 on Tuesday, 22 October 2024. The Company is pleased to announce that Dr Arron Tolley, Chief Executive Officer and Andrew Rapson, Chief Financial Officer will provide a live presentation relating to the full year results via Investor Meet Company on Tuesday, 22 October 2024 at 2:00 pm GMT. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Aptamer Group plc via: hxxps://www.investor Investors who already follow Aptamer Group plc on the Investor Meet Company platform will automatically be invited. |
Posted at 03/7/2024 06:34 by gepetto100 Aptamer Group plc("Aptamer", the "Company" or the "Group")Agreement to explore Optimer vehicles for targeted delivery of siRNA- New collaboration will evaluate Aptamer's fibrotic liver delivery vehicles with siRNA Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce a new agreement with AstraZeneca, a global biopharmaceutical company, to evaluate the Optimer fibrotic liver delivery vehicles for the targeted delivery of siRNA. Following the encouraging results achieved to-date with Aptamer's fibrotic liver delivery vehicles, the next phase of this research will explore the potential of the non-viral delivery vehicle and its applicability with a tool siRNA. Under the agreement, AstraZeneca will provide an siRNA to be trialled with Aptamer's Optimer-based delivery vehicle for fibrotic liver cells. Aptamer Group will conduct in-house experimental work to assess the effectiveness of this delivery vehicle with the AstraZeneca's siRNA. Upon success, Aptamer Group will progress to internally generating demonstrator data in animal models for evaluation by AstraZeneca. Delivery of siRNA to precise cell types and tissues with successful cell internalisation remains a significant challenge for the wider therapeutic application of the technology. Despite this limitation, the siRNA market was still valued at over $13 billion in 2023. Optimer technology could represent a paradigm shift in the targeted delivery of siRNA molecules, due to the high levels of selectivity, high affinity and simple conjugation of siRNA payloads, offered using Optimer delivery systems as non-viral vectors. If successful Optimer-enabled delivery of siRNA could lead to the development of novel compounds that have significant advantages over current cell and tissue-targeting methods. Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "We are really excited to work with AstraZeneca to evaluate and optimise our Optimer delivery vehicles."Partnershi |
Posted at 24/6/2024 06:12 by multibagger Good morning all :)Another excellent RNS and further proof that a number of contracts being signed and many more to come ! RNS Number : 4897T Aptamer Group PLC 24 June 2024 Aptamer Group Announces New Contracts Worth £235,000 for Optimer Development - Contract with top five pharma partner for IHC reagents - Contract to develop Optimer for life science kits with royalty-bearing licence upon commercialisation Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce the signing of two significant contracts for the development of Optimer binders, with a combined total value of up to £235,000. The first contract, valued at up to £175,000, is with a top five pharmaceutical company. As part of this contract, Aptamer will develop Optimer binders for use in immunohistochemistry (IHC) applications. There is potential for the Optimer binders to utilise the Company's recently patented Optimer-Fc platform to deliver advanced IHC reagents for improved performance and use in automated IHC workflows. Following development, the binders could be integrated into companion diagnostics or as critical reagents to support the top five partner's drug development pipeline, resulting in downstream royalties and/or licencing revenues for Aptamer. This agreement represents the sixth contract with this pharmaceutical partner for Optimer development across multiple applications, highlighting its confidence in the Optimer platform. The second contract, valued at up to £60,000, is with a global provider of specialty enzymes used widely throughout the life sciences sector, in a $9.9bn market, growing at 8.6% CAGR. Aptamer will develop Optimer binders as novel reagents to be incorporated into the partner's life science and diagnostic assay kits. Through a non-exclusive licence for the developed Optimer, Aptamer Group will earn milestone payments upon successful commercialisation and downstream high single digit royalties from the gross sales of all kits containing the developed Optimer. Sales could commence as early as 2025. Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "The repeat business from another of our top-five pharma partner validates the power of the Optimer platform to solve intractable problems associated with traditional ligands like antibodies in the area of immunohistochemistry (IHC) and supports our new business and patenting strategy. These smaller royalty bearing agreements to develop Optimer binders aligns with our business model to develop a diversified pipeline of technologies to deliver licence agreements across the life science sector. Unfortunately, due to confidentiality we cannot disclose the name of the partner or any other terms of the deal. Over the past year, the new management team has successfully rebuilt the sales pipeline, and refocused the business to its pre-IPO model which continues to convert to signed deals - with opportunities to generate passive income through licensing and royalty-based deals. I look forward to updating the market on continuing commercial progress and on the continued development of our key assets in delivery vehicles for the Liver Fibrosis, binders for cosmetic applications with Unilever and our ongoing partnership with Neuro-Bio developing a diagnostic for Alzheimer's." - ENDS - |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
